Summary Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia. This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries North America (U.S., Canada, Mexico) Europe (Germany, U.K., France, Italy, Russia, Spain etc) South America (Brazil, Argentina etc) Middle East & Africa (Saudi Arabia, South Africa etc) By Type Exenatied Liraglutide Lixisenatide Albiglutide Dulaglutide By End-User / Application Hospital Pharmacy Others By Company Novo Nordisk AstraZeneca Eli Lily GSK Sanofi Bristol-Myers Squibb Amylin
Table of Contents 1 Market Definition 1.1 Market Segment Overview 1.2 by Type 1.3 by End-Use / Application 2 Global Market by Vendors 2.1 Market Share 2.2 Vendor Profile 2.3 Dynamic of Vendors 3 Global Market by Type 3.1 Market Share 3.2 Introduction of End-Use by Different Products 4 Global Market by End-Use / Application 4.1 Market Share 4.2 Overview of Co
